Complejo Esclerosis Tuberosa, análisis de los ámbitos de afectación, progreso en el tratamiento y traslación a la práctica clínica habitual de dos cohortes de pacientes de edad adulta y pediátrica

Tesis Doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Medicina, Departamento de Pediatría. Fecha de Lectura: 04-06-202

Natural course of septo-optic dysplasia: Retrospective analysis of 20 cases

Introducción. La displasia septoóptica (DSO) es la combinación variable de signos de disgenesia de línea media cerebral, hipoplasia de nervios ópticos y disfunción hipotálamo-hipofisaria, asociándose, a veces, con un espectro variado de malformaciones de la corteza cerebral. Objetivo. Describir la evolución natural y los hallazgos de neuroimagen en una serie de 20 pacientes diagnosticados. Pacientes y métodos. Se revisan de forma retrospectiva las características epidemiológicas, clínicas y neurroradiológicas de 20 pacientes consecutivos diagnosticados de DSO entre enero de 1985 y enero de 2010. Se analizaron los datos de tomografía computarizada, resonancia magnética craneal, electroencefalograma, potenciales evocados visuales, valoración oftalmológica, cariotipo y estudio endocrinológico. En siete pacientes, se realizó estudio del gen Homeobox HESX1. Resultados. El 60% de los casos presentaba antecedentes patológicos en el primer trimestre de gestación, con las ecografías fetales normales. Clínicamente, destacaban manifestaciones visuales (85%), alteraciones endocrinas (50%), retraso mental (60%) y crisis epilépticas (55%). Un 55% se asociaba a anomalías de migración neuronal. En un 45%, la DSO era el único hallazgo de neuroimagen. Se realizó cariotipo a todos, siendo normal. El gen HESX1 fue positivo en dos de los siete casos estudiados (ambos con DSO aislada). Ninguno con mutación en el gen HESX1 presentaba consanguinidad familiar. No se realizó estudio genético a los padres. Conclusiones. La DSO debe clasificarse como un síndrome malformativo heterogéneo, que asocia múltiples anomalías cerebrales, oculares, endocrinas y sistémicas. Las formas más graves se asocian con anomalías de la migración neuronal y de la organización cortical (AU)Introduction. Septo-optic dysplasia (SOD) is the variable combination of signs of dysgenesis of the midline of the brain, hypoplasia of the optic nerves and hypothalamus-pituitary dysfunction, which is sometimes associated with a varied spectrum of malformations of the cerebral cortex. Aims. To describe the natural history and neuroimaging findings in a series of 20 diagnosed patients. Patients and methods. We review the epidemiological, clinical and neuroimaging characteristics of 20 consecutive patients diagnosed with SOD between January 1985 and January 2010. Data obtained from computerised tomography, magnetic resonance imaging of the head, electroencephalogram, visual evoked potentials, ophthalmological evaluation, karyotyping and endocrinological studies were analysed. In seven patients, a study of the gene Homeobox HESX1 was conducted. Results. Pathological antecedents in the first three months of gestation were presented by 60% of the cases, with normal results in the foetal ultrasound scans. Clinically, the most striking features were visual manifestations (85%), endocrine disorders (50%), mental retardation (60%) and epileptic seizures (55%). Fifty-five per cent were associated to abnormal neuronal migration. In 45%, SOD was the only finding in the neuroimaging scans. Karyotyping was performed in all cases, the results being normal. Gene HESX1 was positive in two of the seven cases studied (both with isolated SOD). None of those with mutation in gene HESX1 presented familial consanguinity. No gene study was conducted with the parents. Conclusions. SOD must be classified as a heterogeneous malformation syndrome, which is associated to multiple brain, ocular, endocrine and systemic anomalies. The most severe forms are associated with abnormal neuronal migration and cortical organisation (AU

Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex

Importance Efficacy of cannabidiol has been demonstrated in seizures associated with Lennox-Gastaut and Dravet syndromes but appears not yet to have been established in conditions with primarily focal seizures, such as tuberous sclerosis complex (TSC).Objective To evaluate efficacy and safety of 25-mg/kg/day and 50-mg/kg/day cannabidiol dosages vs placebo against seizures associated with TSC.Design, Setting, and Participants This double-blind, placebo-controlled randomized clinical trial (GWPCARE6) enrolled patients between April 6, 2016, and October 4, 2018; follow-up was completed on February 15, 2019. The trial was conducted at 46 sites in Australia, Poland, Spain, the Netherlands, United Kingdom, and United States. Eligible patients (aged 1-65 years) were those with a clinical diagnosis of TSC and medication-resistant epilepsy who had had at least 8 TSC-associated seizures during the 4-week baseline period, with at least 1 seizure occurring in at least 3 of the 4 weeks, and were currently taking at least 1 antiepileptic medication.Interventions Patients received oral cannabidiol at 25 mg/kg/day (CBD25) or 50 mg/kg/day (CBD50) or a matched placebo for 16 weeks.Main Outcomes and Measures The prespecified primary outcome was the change from baseline in number of TSC-associated seizures for cannabidiol vs placebo during the treatment period.Results Of 255 patients screened for eligibility, 31 were excluded and 224 were randomized. Of the 224 included patients (median [range] age, 11.4 [1.1-56.8] years; 93 female patients [41.5%]), 75 were randomized to CBD25, 73 to CBD50, and 76 to placebo, with 201 completing treatment. The percentage reduction from baseline in the type of seizures considered the primary end point was 48.6% (95% CI, 40.4%-55.8%) for the CBD25 group, 47.5% (95% CI, 39.0%-54.8%) for the CBD50 group, and 26.5% (95% CI, 14.9%-36.5%) for the placebo group; the percentage reduction from placebo was 30.1% (95% CI, 13.9%-43.3%; P < .001) for the CBD25 group and 28.5% (95% CI, 11.9%-42.0%; nominal P = .002) for the CBD50 group. The most common adverse events were diarrhea (placebo group, 19 [25%]; CBD25 group, 23 [31%]; CBD50 group, 41 [56%]) and somnolence (placebo group, 7 [9%]; CBD25 group, 10 [13%]; CBD50 group, 19 [26%]), which occurred more frequently with cannabidiol than placebo. Eight patients in CBD25 group, 10 in CBD50 group, and 2 in the placebo group discontinued treatment because of adverse events. Twenty-eight patients taking cannabidiol (18.9%) had elevated liver transaminase levels vs none taking placebo.Conclusions and Relevance Cannabidiol significantly reduced TSC-associated seizures compared with placebo. The 25-mg/kg/day dosage had a better safety profile than the 50-mg/kg/day dosage

Kleine-Levin syndrome: Differential diagnosis in recurrent encephalitic syndromes in adolescence

Introducción. El síndrome de Kleine-Levin es una enfermedad rara de causa desconocida que se caracteriza por episodios recurrentes autolimitados de hipersomnia acompañados de alteración cognitiva y conductual. Entre los episodios, los pacientes tienen un patrón de sueño y cognitivo normal. Casos clínicos. Se presentan tres pacientes de 14 años, dos chicos y una chica. Comenzaron tras un desencadenante (vacuna, una infección respiratoria por influenza B; en el caso de la chica, coincidían con la menstruación). En el episodio agudo mostraban tendencia al sueño y en vigilia destacaba bradipsiquia, inquietud motora y gran labilidad emocional, con tendencia al llanto y necesidad de la presencia de los familiares. Presentaron una duración aproximada de 10-15 días y periodicidad mensual, y se mostraron asintomáticos entre los episodios. Los tres pacientes fueron valorados por pediatras, diagnosticados y tratados de encefalitis autoinmune. Sólo uno cumplía la tríada típica de hipersomnia, hiperfagia e hipersexualidad, pero ninguno de los tres datos se había recogido en la historia clínica inicial y la familia sólo lo refería tras una anamnesis dirigida. Conclusiones. En el síndrome de Kleine-Levin, los síntomas neurológicos durante el cuadro agudo son aún más frecuentes que los psiquiátricos. La tendencia al sueño y el hecho de que durante la vigilia no estén asintomáticos y se muestren lentos, apáticos, lábiles e irascibles, sitúa en primer lugar la sospecha de síndrome encefalítico. Debemos tener presente esta entidad en encefalitis recurrentes de etiología no filiadaIntroduction. The Kleine-Levin syndrome is a rare disease of unknown origin characterized by recurrent and self-limited episodes of hypersomnia that are also accompanied by a cognitive and behavioral dysfunction. Patients present normal sleeping and behavior patterns between episodes. Case reports. We present three patients who are 14 years old: two boys and one girl. They started having the episodes after a predisposing factor (vaccine, influenza B and menstruation). During the episode they presented hypersomnolence and while wakefulness they were bradipsychic, in motor restlessness and with emotional liability. They also presented a tendency towards crying and claimed the presence of relatives constantly. The episodes lasted between 10 and 15 days and they appeared monthly, being asymptomatic between episodes. All three patients were attended initially by pediatricians, diagnosed and treated as autoimmune encephalitis. Only one of our cases had the three typical symptoms of hypersomnia, hyperfagia and hypersexuality. However, none of the three had been asked initially and the family only referred to it after the directed anamnesis. Conclusions. The Kleine-Levin syndrome presents neurologic symptoms initially more frequently than psychiatric ones. Hypersomnia and behavioural disturbances during wakefulness, bradypsychia, apatheia and emotional liability make us suspect that it could be an encephalitis process. We should be aware of this entity if we face a patient with recurrent encephalitis of unknown origi

Impact of COVID-19 in Immunosuppressed Children With Neuroimmunologic Disorders

Background and Objectives To investigate whether children receiving immunosuppressive therapies for neuroimmunologic disorders had (1) increased susceptibility to SARS-CoV2 infection or to develop more severe forms of COVID-19; (2) increased relapses or autoimmune complications if infected; and (3) changes in health care delivery during the pandemic. Methods Patients with and without immunosuppressive treatment were recruited to participate in a retrospective survey evaluating the period from March 14, 2020, to March 30, 2021. Demographics, clinical features, type of immunosuppressive treatment, suspected or confirmed COVID-19 in the patients or cohabitants, and changes in care delivery were recorded. Results One hundred fifty-three children were included: 84 (55%) female, median age 13 years (interquartile range [8–16] years), 79 (52%) on immunosuppressive treatment. COVID-19 was suspected or confirmed in 17 (11%) (all mild), with a frequency similar in patients with and without immunosuppressive treatment (11/79 [14%] vs 6/74 [8%], p = 0.3085). The frequency of neurologic relapses was similar in patients with (18%) and without (21%) COVID19. Factors associated with COVID-19 included having cohabitants with COVID-19 (p <0.001) and lower blood levels of vitamin D (p = 0.039). Return to face-to-face schooling or mask type did not influence the risk of infection, although 43(28%) children had contact with a classmate with COVID-19. Clinic visits changed from face to face to remote for 120 (79%) patients; 110 (92%) were satisfied with the change. Discussion In this cohort of children with neuroimmunologic disorders, the frequency of COVID-19 was low and not affected by immunosuppressive therapies. The main risk factors for developing COVID-19 were having cohabitants with COVID-19 and low vitamin D level

Enterovirus A71 Infection and Neurologic Disease, Madrid, Spain, 2016

We conducted an observational study from January 2016 through January 2017 of patients admitted to a reference pediatric hospital in Madrid, Spain, for neurologic symptoms and enterovirus infection. Among the 30 patients, the most common signs and symptoms were fever, lethargy, myoclonic jerks, and ataxia. Real-time PCR detected enterovirus in the cerebrospinal fluid of 8 patients, nasopharyngeal aspirate in 17, and anal swab samples of 5. The enterovirus was genotyped for 25 of 30 patients; enterovirus A71 was the most common serotype (21/25) and the only serotype detected in patients with brainstem encephalitis or encephalomyelitis. Treatment was intravenous immunoglobulins for 21 patients and corticosteroids for 17. Admission to the pediatric intensive care unit was required for 14 patients. All patients survived. At admission, among patients with the most severe disease, leukocytes were elevated. For children with brainstem encephalitis or encephalomyelitis, clinicians should look for enterovirus and not limit testing to cerebrospinal fluid